The first orally bioavailable SAM-competitive inhibitor of both wild-type and mutated EZH2 and EZH1 was UNC1999, with the ability to target EZH2MUT DLBCL cell lines [145]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.